1. Market Research
  2. > Gynecological Cancer – Pipeline Review, H1 2013

Gynecological Cancer – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 377 pages

Gynecological Cancer – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gynecological Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gynecological Cancer. Gynecological Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gynecological Cancer.
- A review of the Gynecological Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gynecological Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gynecological Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gynecological Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Gynecological Cancer - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 14
Introduction 15
Global Markets Direct Report Coverage 15
Gynecological Cancer Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Gynecological Cancer 17
Gynecological Cancer Therapeutics under Development by Companies 19
Gynecological Cancer Therapeutics under Investigation by Universities/Institutes 35
Late Stage Products 38
Comparative Analysis 38
Mid Clinical Stage Products 39
Comparative Analysis 39
Early Clinical Stage Products 40
Comparative Analysis 40
Discovery and Pre-Clinical Stage Products 41
Comparative Analysis 41
Gynecological Cancer Therapeutics - Products under Development by Companies 42
Gynecological Cancer Therapeutics - Products under Investigation by Universities/Institutes 65
Companies Involved in Gynecological Cancer Therapeutics Development 69
Bristol-Myers Squibb Company 69
Boehringer Ingelheim GmbH 70
F. Hoffmann-La Roche Ltd. 71
Photocure ASA 72
Helix BioPharma Corp. 73
Amgen Inc. 74
Sanofi-Aventis 75
AstraZeneca PLC 76
Eli Lilly and Company 77
Viralytics Ltd. 78
GlaxoSmithKline plc 79
Bioniche Life Sciences, Inc. 80
Tekmira Pharmaceuticals Corp. 81
Genentech, Inc. 82
Nektar Therapeutics 83
Bavarian Nordic A/S 84
Gilead Sciences, Inc. 85
Daiichi Sankyo Company, Ltd 86
Merck and Co., Inc. 87
AbGenomics International, Inc. 88
FASgen, Inc. 89
Dainippon Sumitomo Pharma Co., Ltd. 90
Oxford BioMedica plc 91
Generex Biotechnology Corporation 92
Amorfix Life Sciences Ltd. 93
Ipsen S.A. 94
MediGene AG 95
Nanotherapeutics, Inc. 96
Prolexys Pharmaceuticals, Inc. 97
Aposense Ltd. 98
Millennium Pharmaceuticals, Inc. 99
Novartis AG 100
Samyang Corporation 101
Aphios Corporation 102
Astellas Pharma Inc. 103
Chong Kun Dang Pharmaceutical 104
Eisai Co., Ltd. 105
ImmunoGen, Inc. 106
Pfizer Inc. 107
Sigma-Tau S.p.A. 108
Sunesis Pharmaceuticals, Inc. 109
SuperGen, Inc. 110
Taiho Pharmaceutical Co., Ltd. 111
Zeria Pharmaceutical Co Ltd 112
Cell Therapeutics, Inc. 113
Santaris Pharma A/S 114
Exelixis, Inc. 115
Aduro BioTech 116
Menarini Group 117
CEL-SCI Corporation 118
Celgene Corporation 119
Onyx Pharmaceuticals, Inc. 120
Bayer AG 121
AntiCancer, Inc. 122
Incyte Corporation 123
Merck KGaA 124
Access Pharmaceuticals, Inc. 125
Advaxis, Inc. 126
3SBio Inc. 127
EntreMed, Inc. 128
Hana Biosciences, Inc. 129
Celldex Therapeutics, Inc. 130
ValiRx Plc 131
Active Biotech AB 132
AEterna Zentaris Inc. 133
ImmunoCellular Therapeutics, Ltd. 134
IMMUNOMEDICS, INC 135
Ariad Pharmaceuticals, Inc. 136
Lorus Therapeutics Inc 137
Marshall Edwards, Inc. 138
AVAX Technologies, Inc. 139
Basilea Pharmaceutica Ltd. 140
Bionomics Limited 141
Northwest Biotherapeutics, Inc. 142
Novogen Limited 143
Cleveland BioLabs, Inc. 144
Oncolytics Biotech Inc. 145
OXiGENE, Inc. 146
Critical Outcome Technologies Inc. 147
Alnylam Pharmaceuticals, Inc 148
Cytokinetics, Inc 149
Telik, Inc. 150
VioQuest Pharmaceuticals, Inc. 151
Dendreon Corporation 152
Transgene SA 153
Prima BioMed Limited 154
Progen Pharmaceuticals Limited 155
Innocell Corporation 156
PharmaGap Inc. 157
Quest PharmaTech Inc. 158
Synta Pharmaceuticals Corp. 159
ThromboGenics NV 160
Oasmia Pharmaceutical AB 161
RXi Pharmaceuticals Corporation 162
GandE Herbal Biotechnology Co., Ltd. 163
Rexahn Pharmaceuticals, Inc. 164
Antigen Express, Inc. 165
Morphotek, Inc. 166
Cancer Research Technology Limited 167
Oryzon 168
Spectrum Pharmaceuticals, Inc. 169
Chipscreen Biosciences Ltd 170
Shantha Biotechnics Limited 171
Supratek Pharma Inc. 172
Nutri Pharma ASA 173
GANYMED Pharmaceuticals AG 174
Acceleron Pharma, Inc. 175
Nerviano Medical Sciences S.r.l. 176
Med Discovery SA 177
Glycotope GmbH 178
Priaxon AG 179
TRION Pharma GmbH 180
Advantagene, Inc. 181
BioNumerik Pharmaceuticals, Inc. 182
Dafra Pharma International Ltd. 183
Alethia Biotherapeutics Inc. 184
OnKor Pharmaceuticals, Inc. 185
Coronado Biosciences, Inc. 186
Cerulean Pharma, Inc. 187
Heat Biologics, Inc. 188
MacroGenics, Inc. 189
ApoImmune, Inc. 190
TetraLogic Pharmaceuticals 191
Fresenius Biotech GmbH 192
Pantarhei Bioscience BV 193
Azaya Therapeutics, Inc. 194
CanBas Co., Ltd. 195
Merrimack Pharmaceuticals, Inc. 196
Spirogen Ltd. 197
Innate Therapeutics Limited 198
Conatus Pharmaceuticals Inc. 199
CritiTech, Inc. 200
Deciphera Pharmaceuticals, LLC 201
Vascular Biogenics Ltd. 202
BioCancell Therapeutics, Inc. 203
Advenchen Laboratories, LLC 204
Onconova Therapeutics, Inc 205
MolMed S.p.A. 206
Viral Genetics, Inc. 207
Genexine Co., Ltd. 208
Immunotope, Inc. 209
Esperance Pharmaceuticals, Inc. 210
Omeros Corporation 211
Bolder Biotechnology, Inc. 212
ImmunoVaccine Technologies Inc. 213
Welichem Biotech Inc. 214
Angstrom Pharmaceuticals, Inc. 215
NewLink Genetics Corporation 216
BT PHARMA 217
PharmaMar, S.A. 218
TVAX Biomedical, LLC 219
Genetic Immunity, LLC 220
Quintessence Biosciences, Inc. 221
VentiRx Pharmaceuticals, Inc. 222
Sirnaomics, Inc. 223
AmpliMed Corporation 224
Tigris Pharmaceuticals, Inc. 225
Viventia Biotechnologies Inc. 226
TRACON Pharmaceuticals, Inc. 227
Medestea Research and Production S.p.A. 228
EndoCeutics, Inc. 229
Advanced Cancer Therapeutics 230
Domainex Ltd. 231
Anaphore, Inc. 232
Clovis Oncology, Inc. 233
Oncolix, Inc. 234
OHR Pharmaceutical Inc. 235
Cancer Therapeutics CRC Pty Ltd 236
BioProspecting NB, Inc. 237
Aragon Pharmaceuticals, Inc. 238
RECEPTA Biopharma S.A. 239
Bioo Therapeutics 240
Jiangsu Kanion Pharmaceutical Co., Ltd. 241
NovaBioMed Inc 242
Xenova Group plc 243
Mycenax Biotech Inc. 244
PepTx, Inc. 245
Mebiopharm Co., Ltd. 246
EyeGene, Inc. 247
Vaccibody AS 248
DEKK-TEC, Inc. 249
Chikujee Therapeutics 250
ISA Pharmaceuticals B.V. 251
TAU Therapeutics, LLC 252
Gradalis Inc. 253
Coridon Pty Ltd 254
Gynecological Cancer - Therapeutics Assessment 255
Assessment by Monotherapy Products 255
Assessment by Combination Products 256
Assessment by Route of Administration 257
Assessment by Molecule Type 260
Drug Profiles 263
AEZS-108 - Drug Profile 263
trebananib - Drug Profile 265
paclitaxel poliglumex - Drug Profile 268
farletuzumab - Drug Profile 272
paclitaxel - Drug Profile 275
interferon alpha-2b - Drug Profile 277
canfosfamide hydrochloride - Drug Profile 278
idronoxil - Drug Profile 282
nintedanib - Drug Profile 284
CVac - Drug Profile 286
tirapazamine - Drug Profile 289
Z-100 - Drug Profile 290
vintafolide - Drug Profile 291
cositecan - Drug Profile 294
nimotuzumab - Drug Profile 296
bevacizumab - Drug Profile 299
pazopanib hydrochloride - Drug Profile 303
trabectedin - Drug Profile 306
ixabepilone - Drug Profile 309
(tegafur + gimeracil + oteracil potassium) - Drug Profile 311
acolbifene hydrochloride - Drug Profile 314
Gynecological Cancer Therapeutics - Drug Profile Updates 315
Gynecological Cancer Therapeutics - Discontinued Products 342
Gynecological Cancer Therapeutics - Dormant Products 346
Gynecological Cancer - Product Development Milestones 366
Featured News and Press Releases 366
Appendix 374
Methodology 374
Coverage 374
Secondary Research 374
Primary Research 374
Expert Panel Validation 374
Contact Us 375
Disclaimer 375



List of Tables

Number of Products Under Development for Gynecological Cancer, H1 2013 19
Products under Development for Gynecological Cancer - Comparative Analysis, H1 2013 20
Number of Products under Development by Companies, H1 2013 22
Number of Products under Investigation by Universities/Institutes, H1 2013 38
Comparative Analysis by Late Stage Development, H1 2013 40
Comparative Analysis by Mid Clinical Stage Development, H1 2013 41
Comparative Analysis by Early Clinical Stage Development, H1 2013 42
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 43
Products under Development by Companies, H1 2013 44
Products under Investigation by Universities/Institutes, H1 2013 67
Bristol-Myers Squibb Company, H1 2013 71
Boehringer Ingelheim GmbH, H1 2013 72
F. Hoffmann-La Roche Ltd., H1 2013 73
Photocure ASA, H1 2013 74
Helix BioPharma Corp., H1 2013 75
Amgen Inc., H1 2013 76
Sanofi-Aventis, H1 2013 77
AstraZeneca PLC, H1 2013 78
Eli Lilly and Company, H1 2013 79
Viralytics Ltd., H1 2013 80
GlaxoSmithKline plc, H1 2013 81
Bioniche Life Sciences, Inc., H1 2013 82
Tekmira Pharmaceuticals Corp., H1 2013 83
Genentech, Inc., H1 2013 84
Nektar Therapeutics, H1 2013 85
Bavarian Nordic A/S, H1 2013 86
Gilead Sciences, Inc., H1 2013 87
Daiichi Sankyo Company, Ltd, H1 2013 88
Merck and Co., Inc., H1 2013 89
AbGenomics International, Inc., H1 2013 90
FASgen, Inc., H1 2013 91
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 92
Oxford BioMedica plc, H1 2013 93
Generex Biotechnology Corporation, H1 2013 94
Amorfix Life Sciences Ltd., H1 2013 95
Ipsen S.A., H1 2013 96
MediGene AG, H1 2013 97
Nanotherapeutics, Inc., H1 2013 98
Prolexys Pharmaceuticals, Inc., H1 2013 99
Aposense Ltd., H1 2013 100
Millennium Pharmaceuticals, Inc., H1 2013 101
Novartis AG, H1 2013 102
Samyang Corporation, H1 2013 103
Aphios Corporation, H1 2013 104
Astellas Pharma Inc., H1 2013 105
Chong Kun Dang Pharmaceutical, H1 2013 106
Eisai Co., Ltd., H1 2013 107
ImmunoGen, Inc., H1 2013 108
Pfizer Inc., H1 2013 109
Sigma-Tau S.p.A., H1 2013 110
Sunesis Pharmaceuticals, Inc., H1 2013 111
SuperGen, Inc., H1 2013 112
Taiho Pharmaceutical Co., Ltd., H1 2013 113
Zeria Pharmaceutical Co Ltd, H1 2013 114
Cell Therapeutics, Inc., H1 2013 115
Santaris Pharma A/S, H1 2013 116
Exelixis, Inc., H1 2013 117
Aduro BioTech, H1 2013 118
Menarini Group, H1 2013 119
CEL-SCI Corporation, H1 2013 120
Celgene Corporation, H1 2013 121
Bayer AG, H1 2013 123
AntiCancer, Inc., H1 2013 124
Incyte Corporation, H1 2013 125
Merck KGaA, H1 2013 126
Access Pharmaceuticals, Inc., H1 2013 127
Advaxis, Inc., H1 2013 128
3SBio Inc., H1 2013 129
EntreMed, Inc., H1 2013 130
Hana Biosciences, Inc., H1 2013 131
Celldex Therapeutics, Inc., H1 2013 132
ValiRx Plc, H1 2013 133
Active Biotech AB, H1 2013 134
AEterna Zentaris Inc., H1 2013 135
ImmunoCellular Therapeutics, Ltd., H1 2013 136
IMMUNOMEDICS, INC, H1 2013 137
Ariad Pharmaceuticals, Inc., H1 2013 138
Lorus Therapeutics Inc, H1 2013 139
Marshall Edwards, Inc., H1 2013 140
Basilea Pharmaceutica Ltd., H1 2013 142
Bionomics Limited, H1 2013 143
Northwest Biotherapeutics, Inc., H1 2013 144
Novogen Limited, H1 2013 145
Cleveland BioLabs, Inc., H1 2013 146
Oncolytics Biotech Inc., H1 2013 147
OXiGENE, Inc., H1 2013 148
Critical Outcome Technologies Inc., H1 2013 149
Alnylam Pharmaceuticals, Inc, H1 2013 150
Cytokinetics, Inc, H1 2013 151
Telik, Inc., H1 2013 152
VioQuest Pharmaceuticals, Inc., H1 2013 153
Dendreon Corporation, H1 2013 154
Transgene SA, H1 2013 155
Progen Pharmaceuticals Limited, H1 2013 157
Innocell Corporation, H1 2013 158
PharmaGap Inc., H1 2013 159
Quest PharmaTech Inc., H1 2013 160
Synta Pharmaceuticals Corp., H1 2013 161
ThromboGenics NV, H1 2013 162
Oasmia Pharmaceutical AB, H1 2013 163
GandE Herbal Biotechnology Co., Ltd., H1 2013 165
Rexahn Pharmaceuticals, Inc., H1 2013 166
Antigen Express, Inc., H1 2013 167
Morphotek, Inc., H1 2013 168
Cancer Research Technology Limited, H1 2013 169
Oryzon, H1 2013 170
Spectrum Pharmaceuticals, Inc., H1 2013 171
Chipscreen Biosciences Ltd, H1 2013 172
Shantha Biotechnics Limited, H1 2013 173
Supratek Pharma Inc., H1 2013 174
Nutri Pharma ASA, H1 2013 175
GANYMED Pharmaceuticals AG, H1 2013 176
Acceleron Pharma, Inc., H1 2013 177
Nerviano Medical Sciences S.r.l., H1 2013 178
Med Discovery SA, H1 2013 179
Priaxon AG, H1 2013 181
TRION Pharma GmbH, H1 2013 182
BioNumerik Pharmaceuticals, Inc., H1 2013 184
Dafra Pharma International Ltd., H1 2013 185
Alethia Biotherapeutics Inc., H1 2013 186
OnKor Pharmaceuticals, Inc., H1 2013 187
Coronado Biosciences, Inc., H1 2013 188
Cerulean Pharma, Inc., H1 2013 189
Heat Biologics, Inc., H1 2013 190
MacroGenics, Inc., H1 2013 191
ApoImmune, Inc., H1 2013 192
TetraLogic Pharmaceuticals, H1 2013 193
Fresenius Biotech GmbH, H1 2013 194
Pantarhei Bioscience BV, H1 2013 195
Azaya Therapeutics, Inc., H1 2013 196
CanBas Co., Ltd., H1 2013 197
Merrimack Pharmaceuticals, Inc., H1 2013 198
Spirogen Ltd., H1 2013 199
Innate Therapeutics Limited, H1 2013 200
Conatus Pharmaceuticals Inc., H1 2013 201
CritiTech, Inc., H1 2013 202
Deciphera Pharmaceuticals, LLC, H1 2013 203
Vascular Biogenics Ltd., H1 2013 204
BioCancell Therapeutics, Inc., H1 2013 205
Advenchen Laboratories, LLC, H1 2013 206
Onconova Therapeutics, Inc, H1 2013 207
MolMed S.p.A., H1 2013 208
Viral Genetics, Inc., H1 2013 209
Genexine Co., Ltd., H1 2013 210
Immunotope, Inc., H1 2013 211
Esperance Pharmaceuticals, Inc., H1 2013 212
Omeros Corporation, H1 2013 213
Bolder Biotechnology, Inc., H1 2013 214
ImmunoVaccine Technologies Inc., H1 2013 215
Welichem Biotech Inc., H1 2013 216
Angstrom Pharmaceuticals, Inc., H1 2013 217
BT PHARMA, H1 2013 219
PharmaMar, S.A., H1 2013 220
TVAX Biomedical, LLC, H1 2013 221
Genetic Immunity, LLC, H1 2013 222
Quintessence Biosciences, Inc., H1 2013 223
VentiRx Pharmaceuticals, Inc., H1 2013 224
Sirnaomics, Inc., H1 2013 225
AmpliMed Corporation, H1 2013 226
Tigris Pharmaceuticals, Inc., H1 2013 227
Viventia Biotechnologies Inc., H1 2013 228
TRACON Pharmaceuticals, Inc., H1 2013 229
Medestea Research and Production S.p.A., H1 2013 230
EndoCeutics, Inc., H1 2013 231
Advanced Cancer Therapeutics, H1 2013 232
Domainex Ltd., H1 2013 233
Anaphore, Inc., H1 2013 234
Oncolix, Inc., H1 2013 236
OHR Pharmaceutical Inc., H1 2013 237
Cancer Therapeutics CRC Pty Ltd, H1 2013 238
BioProspecting NB, Inc., H1 2013 239
Aragon Pharmaceuticals, Inc., H1 2013 240
RECEPTA Biopharma S.A., H1 2013 241
Bioo Therapeutics, H1 2013 242
Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2013 243
NovaBioMed Inc, H1 2013 244
Xenova Group plc, H1 2013 245
Mycenax Biotech Inc., H1 2013 246
PepTx, Inc., H1 2013 247
Mebiopharm Co., Ltd., H1 2013 248
EyeGene, Inc., H1 2013 249
Vaccibody AS, H1 2013 250
DEKK-TEC, Inc., H1 2013 251
Chikujee Therapeutics, H1 2013 252
ISA Pharmaceuticals B.V., H1 2013 253
TAU Therapeutics, LLC, H1 2013 254
Gradalis Inc., H1 2013 255
Coridon Pty Ltd, H1 2013 256
Assessment by Monotherapy Products, H1 2013 257
Assessment by Combination Products, H1 2013 258
Assessment by Stage and Route of Administration, H1 2013 261
Assessment by Stage and Molecule Type, H1 2013 264
Gynecological Cancer Therapeutics - Drug Profile Updates 317
Gynecological Cancer Therapeutics - Discontinued Products 344
Gynecological Cancer Therapeutics - Dormant Products 348



List of Figures

Number of Products under Development for Gynecological Cancer, H1 2013 19
Products under Development for Gynecological Cancer - Comparative Analysis, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Investigation by Universities/Institutes, H1 2013 37
Late Stage Products, H1 2013 40
Mid Clinical Stage Products, H1 2013 41
Early Clinical Stage Products, H1 2013 42
Discovery and Pre-Clinical Stage Products, H1 2013 43
Assessment by Monotherapy Products, H1 2013 257
Assessment by Combination Products, H1 2013 258
Assessment by Route of Administration, H1 2013 259
Assessment by Stage and Route of Administration, H1 2013 260
Assessment by Molecule Type, H1 2013 262
Assessment by Stage and Molecule Type, H1 2013 263

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.